Ipsen finalizes purchase of Albireo Pharma to strengthen its rare disease portfolio | HealthCare Middle East & Africa Magazine
Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association
Limb Spasm Treatments for MS Patients Explored by Flex Pharma, Ipsen Biopharmaceuticals
Ipsen gets U.S. manufacturing with $1.25B deal for Merrimack Pharmaceuticals | Fierce Pharma
Clinical Trial Associate job in Cambridge, Massachusetts, United States of America | Medical & Clinical jobs at IPSEN
Is Ipsen late reporting EU clinical trials?
Ipsen on LinkedIn: Ipsen announces positive clinical trial findings in patients living with… | 23 comments
PharmaBoardroom - Problems Pile Up at Ipsen after Further Clinical Setback
How the FDA Stifles New Cures, Part II: 90% of Clinical Trial Costs are Incurred in Phase III
Clinical Trial Associate job with Ipsen Biopharmaceuticals, Inc. | 2725115
Ipsen announces additional Phase III study results for Dysport
Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease - MedCity News
French Biopharma Gets Cancer Drug for €700M
Ipsen's rare disease drug palovarotene knocked back in EU | pharmaphorum
Ipsen - Innovation for patient care - Ipsen
Ipsen reports data from pancreatic ductal adenocarcinoma trial
Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease
Two Ipsen Clinical Trials Released on ClinicalTrials.gov
Clinical trials - Ipsen
Discover Ipsen new clinical trials section - Ipsen
Ipsen Becomes First to Best Standard of Care in Metastatic PDAC | BioSpace
Clinical trials - Ipsen
Irlab's Ipsen-partnered Parkinson's drug flunks phase 2 trial
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
